Menu

About Us

COVID FRONTLINE Initiative

Welcome to COVID FRONTLINE, an information hub and resource center on the rapidly evolving COVID-19 pandemic.

COVID-19 first emerged in China in December 2019 and was declared a global pandemic in March 2020. The rapid increase of critically ill patients with pneumonia and the absence of definitive treatment quickly overwhelmed healthcare systems. With confirmed COVID-19 cases continuing to grow, scientists are pushing forward with efforts to develop vaccines and treatments to slow the pandemic and lessen the damage from this novel virus.

New data regarding COVID-19 are emerging daily. Clinicians require up-to-date resources on current treatment guidelines and clinical trial data on effective therapies and vaccines to improve clinical outcomes, minimize patient harm, and ensure consistency in care. The general population needs the latest information on the virus in order to limit its transmission and prevent future infections.

Please click on the links to the Clinical Care and Patient Toolkits to find up-to-date information on the prevention, diagnosis and management of COVID-19.

About Med Learning Group

Med Learning Group, a division of Ultimate Medical Academy, is a full-service, accredited medical education company. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for both the patient and the practitioner.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive, and patient-centric in nature. We apply adult learning theory and principles to our programs and, more importantly, understand the nuances of our specialty audiences. We design programs for physicians, nurses, pharmacists, and other healthcare practitioners and have a deep understanding of how to educate both specialty audiences and general practitioners. The mission of Med Learning Group is to design educational activities for healthcare practitioners that increase competence, change behavior, and optimize patient care. The major focus of our education is the creation of innovative and interactive educational programs designed with scientific rigor, fair balance, and evidence-based content.

Menu

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

First Single-Dose COVID-19 Vaccine Authorized for Emergency Use

On February 27, 2021, the US Food and Drug Administration (FDA) authorized a single-dose vaccine for emergency use to prevent COVID-19 in individuals 18 years of age and older. The FDA partly based its decision on data from the phase 3 EMSEMBLE trial, which was conducted in eight countries across three continents and included patients infected with emerging viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data from this study demonstrated that the vaccine was 85% effective in preventing severe disease across all geographic regions studied. The level of protection against moderate and severe COVID-19 was 72% in the United States. The vaccine also provided protection against COVID-19-related hospitalization and death, beginning 28 days after vaccination. The Ad.26.COV2.S vaccine is a recombinant vector vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson that uses a human adenovirus to express the SARS-CoV-2 spike protein.

References:

National Institutes of Health (NIH). Janssen investigational COVID-19 vaccine: interim analysis of phase 3 clinical data released. January 29, 2021. Available at www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released  Accessed 3/2/2021.

Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—first single-shot vaccine in fight against global pandemic. February 27, 2021. Available at www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic  Accessed 3/2/2021.